Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unintended Consequences Of Broad Opioid-Sparing Claims Worries US Panel

Executive Summary

FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices. 

Related Content

US FDA Faced With Suite Of Opinions Defining 'Clinically Meaningful' Opioid-Sparing Claims
US FDA Launches Study Of Prescriber Perceptions About Abuse-Deterrent Opioids
Opioid-Sparing Regimens Face High Hurdles After US FDA Advisory Cmte.
US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids
Pfizer paying out millions, again, to settle off-label promotion charges in the US





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts